These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24164581)

  • 1. Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.
    Qiao JX; Wang TC; Ruel R; Thibeault C; L'Heureux A; Schumacher WA; Spronk SA; Hiebert S; Bouthillier G; Lloyd J; Pi Z; Schnur DM; Abell LM; Hua J; Price LA; Liu E; Wu Q; Steinbacher TE; Bostwick JS; Chang M; Zheng J; Gao Q; Ma B; McDonnell PA; Huang CS; Rehfuss R; Wexler RR; Lam PY
    J Med Chem; 2013 Nov; 56(22):9275-95. PubMed ID: 24164581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.
    Jeon YT; Yang W; Qiao JX; Li L; Ruel R; Thibeault C; Hiebert S; Wang TC; Wang Y; Liu Y; Clark CG; Wong HS; Zhu J; Wu DR; Sun D; Chen BC; Mathur A; Chacko SA; Malley M; Chen XQ; Shen H; Huang CS; Schumacher WA; Bostwick JS; Stewart AB; Price LA; Hua J; Li D; Levesque PC; Seiffert DA; Rehfuss R; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1294-8. PubMed ID: 24513044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.
    Wang TC; Qiao JX; Clark CG; Jua J; Price LA; Wu Q; Chang M; Zheng J; Huang CS; Everlof G; Schumacher WA; Wong PC; Seiffert DA; Stewart AB; Bostwick JS; Crain EJ; Watson CA; Rehfuss R; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3239-43. PubMed ID: 23602442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Benzothiazole-7-hydroxyindolinyl diaryl ureas are potent P2Y1 antagonists with favorable pharmacokinetics: low clearance and small volume of distribution.
    Qiao JX; Wang TC; Hiebert S; Hu CH; Schumacher WA; Spronk SA; Clark CG; Han Y; Hua J; Price LA; Shen H; Chacko SA; Everlof G; Bostwick JS; Steinbacher TE; Li YX; Huang CS; Seiffert DA; Rehfuss R; Wexler RR; Lam PY
    ChemMedChem; 2014 Oct; 9(10):2327-43. PubMed ID: 24989964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.
    Chao H; Turdi H; Herpin TF; Roberge JY; Liu Y; Schnur DM; Poss MA; Rehfuss R; Hua J; Wu Q; Price LA; Abell LM; Schumacher WA; Bostwick JS; Steinbacher TE; Stewart AB; Ogletree ML; Huang CS; Chang M; Cacace AM; Arcuri MJ; Celani D; Wexler RR; Lawrence RM
    J Med Chem; 2013 Feb; 56(4):1704-14. PubMed ID: 23368907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.
    Yang W; Wang Y; Lai A; Qiao JX; Wang TC; Hua J; Price LA; Shen H; Chen XQ; Wong P; Crain E; Watson C; Huang CS; Seiffert DA; Rehfuss R; Wexler RR; Lam PY
    J Med Chem; 2014 Jul; 57(14):6150-64. PubMed ID: 24931384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of 2-(phenoxyaryl)-3-urea derivatives as novel P2Y
    Peng J; Zhao L; Wang L; Chen H; Qiu Y; Wang J; Yang H; Liu J; Liu H
    Eur J Med Chem; 2018 Oct; 158():302-310. PubMed ID: 30223118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents.
    Pi Z; Sutton J; Lloyd J; Hua J; Price L; Wu Q; Chang M; Zheng J; Rehfuss R; Huang CS; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4206-9. PubMed ID: 23743287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Amino-1,3,4-thiadiazoles in the 7-hydroxy-N-neopentyl spiropiperidine indolinyl series as potent P2Y1 receptor antagonists.
    Hu CH; Qiao JX; Han Y; Wang TC; Hua J; Price LA; Wu Q; Shen H; Huang CS; Rehfuss R; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2481-5. PubMed ID: 24767843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y
    Lei Y; Zhang B; Liu D; Zhao J; Dai X; Gao J; Mao Q; Feng Y; Zhao J; Lin F; Duan Y; Zhang Y; Bao Z; Yang Y; Mou Y; Wang S
    J Med Chem; 2020 Dec; 63(24):15752-15772. PubMed ID: 33307675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists.
    Thalji RK; Aiyar N; Davenport EA; Erhardt JA; Kallal LA; Morrow DM; Senadhi S; Burns-Kurtis CL; Marino JP
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4104-7. PubMed ID: 20542694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New azole antagonists with high affinity for the P2Y(1) receptor.
    Ruel R; L'Heureux A; Thibeault C; Daris JP; Martel A; Price LA; Wu Q; Hua J; Wexler RR; Rehfuss R; Lam PY
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3519-22. PubMed ID: 23668989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.
    Shen DM; Zhang F; Brady EJ; Candelore MR; Dallas-Yang Q; Ding VD; Dragovic J; Feeney WP; Jiang G; McCann PE; Mock S; Qureshi SA; Saperstein R; Shen X; Tamvakopoulos C; Tong X; Tota LM; Wright MJ; Yang X; Zheng S; Chapman KT; Zhang BB; Tata JR; Parmee ER
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4564-9. PubMed ID: 16102966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies towards the development of a PET radiotracer for imaging of the P2Y
    Moldovan RP; Wenzel B; Teodoro R; Neumann W; Dukic-Stefanovic S; Kraus W; Rong P; Deuther-Conrad W; Hey-Hawkins E; Krügel U; Brust P
    Eur J Med Chem; 2019 Mar; 165():142-159. PubMed ID: 30665144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds.
    Ruel R; L'Heureux A; Thibeault C; Lapointe P; Martel A; Qiao JX; Hua J; Price LA; Wu Q; Chang M; Zheng J; Huang CS; Wexler RR; Rehfuss R; Lam PY
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6825-8. PubMed ID: 24269480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two disparate ligand-binding sites in the human P2Y1 receptor.
    Zhang D; Gao ZG; Zhang K; Kiselev E; Crane S; Wang J; Paoletta S; Yi C; Ma L; Zhang W; Han GW; Liu H; Cherezov V; Katritch V; Jiang H; Stevens RC; Jacobson KA; Zhao Q; Wu B
    Nature; 2015 Apr; 520(7547):317-21. PubMed ID: 25822790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
    Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL
    Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of P2Y
    Kong D; Xue T; Guo B; Cheng J; Liu S; Wei J; Lu Z; Liu H; Gong G; Lan T; Hu W; Yang Y
    J Med Chem; 2019 Mar; 62(6):3088-3106. PubMed ID: 30843696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BPTU, an allosteric antagonist of P2Y1 receptor, blocks nerve mediated inhibitory neuromuscular responses in the gastrointestinal tract of rodents.
    Mañé N; Jiménez-Sábado V; Jiménez M
    Neuropharmacology; 2016 Nov; 110(Pt A):376-385. PubMed ID: 27496690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.